Premium
Synthesis, In Vitro Biological Evaluation, and Molecular Docking of New Triazoles as Potent Antifungal Agents
Author(s) -
Li Xiang,
Liu Chao,
Tang Sheng,
Wu Qiuye,
Hu Honggang,
Zhao Qingjie,
Zou Yan
Publication year - 2016
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201500313
Subject(s) - in vitro , docking (animal) , chemistry , antifungal , cycloaddition , triazole , stereochemistry , azole , combinatorial chemistry , biological activity , broad spectrum , active site , click chemistry , biochemistry , organic chemistry , enzyme , biology , catalysis , microbiology and biotechnology , medicine , nursing
Based on the structure of the active site of CYP51 and the structure–activity relationships of azole antifungal compounds that we designed in a previous study, a series of 1‐{1‐[2‐(substitutedbenzyloxy)ethyl]‐1 H ‐1,2,3‐triazol‐4‐yl}‐2‐(2,4‐difluorophenyl)‐3‐(1 H ‐1,2,4‐triazol‐1‐yl)propan‐2‐ols ( 6a – n ) were designed and synthesized utilizing copper‐catalyzed azide‐alkyne cycloaddition. Preliminary antifungal tests against eight human pathogenic fungi in vitro showed that all the title compounds exhibited excellent antifungal activities with a broad spectrum in vitro . Molecular docking results indicated that the interaction between the title compounds and CYP51 comprised π–π interactions, hydrophobic interactions, and the narrow hydrophobic cleft.